Revenues for the quarter increased to $19.6 million from $7.3 million during the same quarter last year. Most of this boost resulted from increased sales of reagents and disposables, Cepheid said.
Research and development costs climbed to $4.5 million from $3.6 million during the same period a year ago.
Cepheid's net loss narrowed to $3.5 million, or $.08 per share, from $4.1 million, or $.11 per share, during the year-ago period.
As of March 31, Cepheid had $21.4 million in cash and cash equivalents, and $33.5 million in marketable securities.